MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 333052 | Name: Micafungin
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Micafungin, also known as FK463, is a polyene antifungal medication used to treat and prevent invasive fungal infections including candidemia, abscesses and esophageal candidiasis. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. It received final approval from the U.S. Food and Drug Administration (FDA) on March 16, 2005. Micafungin works by way of concentration-dependent inhibition of 1,3-beta-D-glucan synthase resulting in reduced formation of 1,3-beta-D-glucan, which is an essential polysaccharide comprising one-third of the majority of Candida spp. cell walls. This decreased glucan production leads to osmotic instability and thus cellular lysis.

Chemical Structure

Micafungin
Micafungin
CAS#235114-32-6 (free acid)

Theoretical Analysis

MedKoo Cat#: 333052

Name: Micafungin

CAS#: 235114-32-6 (free acid)

Chemical Formula: C56H71N9O23S

Exact Mass: 1269.4380

Molecular Weight: 1270.28

Elemental Analysis: C, 52.95; H, 5.63; N, 9.92; O, 28.97; S, 2.52

Price and Availability

Size Price Availability Quantity
25mg USD 150.00 2 Weeks
100mg USD 350.00 2 Weeks
200mg USD 550.00 2 Weeks
500mg USD 950.00 2 Weeks
1g USD 1,650.00 2 Weeks
5g USD 4,950.00 2 Weeks
10g USD 7,650.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
208538-73-2 (sodium) 235114-32-6 (free acid)
Synonym
Micafungin; Mycamine; FK463; FK-463; FK 463;
IUPAC/Chemical Name
5-((1S,2S)-2-((2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-20-((R)-3-amino-1-hydroxy-3-oxopropyl)-2,11,12,15-tetrahydroxy-6-((R)-1-hydroxyethyl)-16-methyl-5,8,14,19,22,25-hexaoxo-9-(4-(5-(4-(pentyloxy)phenyl)isoxazol-3-yl)benzamido)tetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-23-yl)-1,2-dihydroxyethyl)-2-hydroxyphenyl hydrogen sulfate
InChi Key
PIEUQSKUWLMALL-YABMTYFHSA-N
InChi Code
InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1
SMILES Code
CCCCCOC1=CC=C(C2=CC(C3=CC=C(C(N[C@H]4C[C@H]([C@H](NC([C@@H]5[C@H]([C@H](CN5C([C@H]([C@@H](CC(N)=O)O)NC([C@H]([C@@H]([C@H](C6=CC(OS(=O)(O)=O)=C(O)C=C6)O)O)NC([C@@H]7C[C@H](CN7C([C@H]([C@H](O)C)NC4=O)=O)O)=O)=O)=O)C)O)=O)O)O)=O)C=C3)=NO2)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Micafungin (Mycamine; FK463) is an echinocandin antifungal drug which can inhibit 1,3-beta-D-glucan synthase.
In vitro activity:
This is the first study demonstrating the effectiveness of micafungin in inhibiting the cytopathic effects of dengue virus serotype 2 (DENV-2) in a dose-dependent manner. Time-of-addition assays verified the inhibitory effects of micafungin in pre-treated, co-treated, and full-treatment groups. The virucidal efficacy of micafungin appears to lie in its ability to destroy the virion. Molecular docking assays revealed the binding of micafungin to the envelope protein of DENV-2, thereby revealing the mechanism by which micafungin affects the early stage of DENV infection and the stability of DENV. Reference: Pharmaceuticals (Basel). 2021 Apr 7;14(4):338. https://pubmed.ncbi.nlm.nih.gov/33917182/
In vivo activity:
Proliferative Candida invasion into the peritoneum and intra-abdominal organs was confirmed pathologically only in the PF mice. However, all mice in both groups treated with micafungin survived until day 20. Micafungin treatment tends to suppress inflammatory cytokines in the plasma 12 h after infection in both groups. Reference: Sci Rep. 2019 Jun 27;9(1):9331. https://pubmed.ncbi.nlm.nih.gov/31249356/

Preparing Stock Solutions

The following data is based on the product molecular weight 1,270.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Chen YC, Lu JW, Yeh CT, Lin TY, Liu FC, Ho YJ. Micafungin Inhibits Dengue Virus Infection through the Disruption of Virus Binding, Entry, and Stability. Pharmaceuticals (Basel). 2021 Apr 7;14(4):338. doi: 10.3390/ph14040338. PMID: 33917182; PMCID: PMC8067805. 2. Ho YJ, Liu FC, Yeh CT, Yang CM, Lin CC, Lin TY, Hsieh PS, Hu MK, Gong Z, Lu JW. Micafungin is a novel anti-viral agent of chikungunya virus through multiple mechanisms. Antiviral Res. 2018 Nov;159:134-142. doi: 10.1016/j.antiviral.2018.10.005. Epub 2018 Oct 6. PMID: 30300716. 3. Ashizawa N, Miyazaki T, Abe S, Takazono T, Saijo T, Obata Y, Shimamura S, Yamamoto K, Imamura Y, Koji T, Nishino T, Izumikawa K, Yanagihara K, Kohno S, Mukae H. Evaluation of Candida peritonitis with underlying peritoneal fibrosis and efficacy of micafungin in murine models of intra-abdominal candidiasis. Sci Rep. 2019 Jun 27;9(1):9331. doi: 10.1038/s41598-019-45776-x. PMID: 31249356; PMCID: PMC6597535. 4. Salinas B, Guembe M, Cussó L, Kestler M, Guinea J, Desco M, Muñoz P, Bouza E. Assessment of the anti-biofilm effect of micafungin in an animal model of catheter-related candidemia. Med Mycol. 2019 Jun 1;57(4):496-503. doi: 10.1093/mmy/myy065. PMID: 30212901.
In vitro protocol:
1. Chen YC, Lu JW, Yeh CT, Lin TY, Liu FC, Ho YJ. Micafungin Inhibits Dengue Virus Infection through the Disruption of Virus Binding, Entry, and Stability. Pharmaceuticals (Basel). 2021 Apr 7;14(4):338. doi: 10.3390/ph14040338. PMID: 33917182; PMCID: PMC8067805. 2. Ho YJ, Liu FC, Yeh CT, Yang CM, Lin CC, Lin TY, Hsieh PS, Hu MK, Gong Z, Lu JW. Micafungin is a novel anti-viral agent of chikungunya virus through multiple mechanisms. Antiviral Res. 2018 Nov;159:134-142. doi: 10.1016/j.antiviral.2018.10.005. Epub 2018 Oct 6. PMID: 30300716.
In vivo protocol:
1. Ashizawa N, Miyazaki T, Abe S, Takazono T, Saijo T, Obata Y, Shimamura S, Yamamoto K, Imamura Y, Koji T, Nishino T, Izumikawa K, Yanagihara K, Kohno S, Mukae H. Evaluation of Candida peritonitis with underlying peritoneal fibrosis and efficacy of micafungin in murine models of intra-abdominal candidiasis. Sci Rep. 2019 Jun 27;9(1):9331. doi: 10.1038/s41598-019-45776-x. PMID: 31249356; PMCID: PMC6597535. 2. Salinas B, Guembe M, Cussó L, Kestler M, Guinea J, Desco M, Muñoz P, Bouza E. Assessment of the anti-biofilm effect of micafungin in an animal model of catheter-related candidemia. Med Mycol. 2019 Jun 1;57(4):496-503. doi: 10.1093/mmy/myy065. PMID: 30212901.
1: Spettel K, Galazka S, Kriz R, Camp I, Willinger B. Do Candida albicans Isolates with Borderline Resistant Micafungin MICs Always Harbor FKS1 Hot Spot Mutations? J Fungi (Basel). 2021 Jan 28;7(2):93. doi: 10.3390/jof7020093. PMID: 33525326. 2: Taormina G, Gopinath R, Moore J, Yasinskaya Y, Colangelo P, Reynolds K, Nambiar S. A Regulatory Review Approach for Evaluation of Micafungin for Treatment of Neonatal Candidiasis. Clin Infect Dis. 2021 Jan 18:ciab025. doi: 10.1093/cid/ciab025. Epub ahead of print. PMID: 33458754. 3: Zhong S, Zhu X, Zhao L, Song Y, Yu J, Zheng Z, Zang B. Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis. Pharm Res. 2021 Jan 6. doi: 10.1007/s11095-020-02980-z. Epub ahead of print. PMID: 33404989. 4: Wingen-Heimann SM, Cornely OA, J G T Vehreschild M, Wisplinghoff H, Franke B, Schons M, von Bergwelt-Baildon M, Scheid C, Vehreschild JJ. Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six-year cohort analysis. Mycoses. 2020 Dec 22. doi: 10.1111/myc.13232. Epub ahead of print. PMID: 33354800. 5: Alonso-Monge R, Guirao-Abad JP, Sánchez-Fresneda R, Pla J, Yagüe G, Argüelles JC. The Fungicidal Action of Micafungin is Independent on Both Oxidative Stress Generation and HOG Pathway Signaling in Candida albicans. Microorganisms. 2020 Nov 26;8(12):1867. doi: 10.3390/microorganisms8121867. PMID: 33256159; PMCID: PMC7768384. 6: Mullins C, Beaulac K, Sylvia L. Reply: Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment. Ann Pharmacother. 2020 Nov 15:1060028020973607. doi: 10.1177/1060028020973607. Epub ahead of print. PMID: 33191775. 7: Danjuma M, Elgara M, Al-Hattab F, Abaro R, Elzouki AN. Comment: Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment. Ann Pharmacother. 2020 Nov 13:1060028020973614. doi: 10.1177/1060028020973614. Epub ahead of print. PMID: 33185108. 8: Arastehfar A, Daneshnia F, Hilmioglu-Polat S, Ilkit M, Yasar M, Polat F, Metin DY, Dokumcu ÜZ, Pan W, Hagen F, Boekhout T, Perlin DS, Lass-Flörl C. Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge? J Antimicrob Chemother. 2021 Jan 19;76(2):418-422. doi: 10.1093/jac/dkaa419. PMID: 33175162. 9: Kimura SI, Kanda Y, Iino M, Fukuda T, Sakaida E, Oyake T, Yamaguchi H, Fujiwara SI, Jo Y, Okamoto A, Fujita H, Takamatsu Y, Saburi Y, Matsumura I, Yamanouchi J, Shiratori S, Gotoh M, Nakamura S, Tamura K; Japan Febrile Neutropenia Study Group. Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial. Int J Infect Dis. 2020 Nov;100:292-297. doi: 10.1016/j.ijid.2020.08.081. Epub 2020 Sep 3. PMID: 32891738. 10: Tóth Z, Forgács L, Kardos T, Kovács R, Locke JB, Kardos G, Nagy F, Borman AM, Adnan A, Majoros L. Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species. J Fungi (Basel). 2020 Aug 17;6(3):136. doi: 10.3390/jof6030136. PMID: 32824464; PMCID: PMC7560028. 11: Kapralos I, Mainas E, Neroutsos E, Apostolidi S, Siopi M, Apostolopoulou O, Dimopoulos G, Sambatakou H, Valsami G, Meletiadis J, Dokoumetzidis A. Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose? J Pharm Pharmacol. 2020 Dec;72(12):1750-1760. doi: 10.1111/jphp.13353. Epub 2020 Aug 12. PMID: 32789881. 12: Warn P, Thommes P, Sharp A, Sattar A, Undre N, Palacios-Fabrega JA, Karas A. Intermittent micafungin for prophylaxis in a rat model of chronic Candida albicans gut colonization. J Antimicrob Chemother. 2020 Oct 1;75(10):2919-2924. doi: 10.1093/jac/dkaa243. PMID: 32719853. 13: Suh JW, Kim SB, Yoon YK, Sohn JW, Kim MJ, Kim JH. Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients. Mycopathologia. 2020 Aug;185(4):653-664. doi: 10.1007/s11046-020-00471-8. Epub 2020 Jul 23. PMID: 32705415; PMCID: PMC7377311. 14: López-Sánchez M, Moreno-Puigdollers I, Rubio-López MI, Zarragoikoetxea- Jauregui I, Vicente-Guillén R, Argente-Navarro MP. Pharmacokinetics of micafungin in patients treated with extracorporeal membrane oxygenation: an observational prospective study. Rev Bras Ter Intensiva. 2020 Jun;32(2):277-283. doi: 10.5935/0103-507x.20200044. Epub 2020 Jul 13. PMID: 32667449; PMCID: PMC7405733. 15: Prabhudas-Strycker KK, Butt S, Reddy MT. Candida tropicalis endocarditis successfully treated with AngioVac and micafungin followed by long- term isavuconazole suppression. IDCases. 2020 Jun 26;21:e00889. doi: 10.1016/j.idcr.2020.e00889. PMID: 32642436; PMCID: PMC7332520. 16: Marx J, Welte R, Gasperetti T, Moser P, Beer R, Ortler M, Jeske M, Stern R, Pomaroli A, Joannidis M, Bellmann R. Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00275-20. doi: 10.1128/AAC.00275-20. PMID: 32340985; PMCID: PMC7318006. 17: van Egmond JC, Hunfeld NGM, Rijnders BJA, Verhaar JAN. Persistent candida arthritis successfully treated with micafungin instillation and surgery. A case report. Med Mycol Case Rep. 2019 Dec 17;27:29-31. doi: 10.1016/j.mmcr.2019.12.011. Erratum in: Med Mycol Case Rep. 2020 Nov 19;30:52. PMID: 32123657; PMCID: PMC7036544. 18: Vena A, Bouza E, Bassetti M, Menichetti F, Merelli M, Grau S, Fortun J, Sánchez MI, Aguado JM, Merino P, Bonache F, Muñoz P. Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Child-Pugh B or C Liver Disease: A Case-Control Retrospective Study. Infect Dis Ther. 2020 Mar;9(1):151-163. doi: 10.1007/s40121-020-00282-w. Epub 2020 Feb 21. PMID: 32086777; PMCID: PMC7054556. 19: Marena GD, Dos Santos Ramos MA, Bauab TM, Chorilli M. Biological Properties and Analytical Methods for Micafungin: A Critical Review. Crit Rev Anal Chem. 2020 Feb 16:1-17. doi: 10.1080/10408347.2020.1726726. Epub ahead of print. PMID: 32064916. 20: López-Sánchez C, Valcárcel D, Gómez V, López-Jiménez J, Serrano D, Rubio V, Solano C, Vázquez L, Ruiz I; Grupo Español de Trasplante Hematopoyético (GETH). Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC). Rev Esp Quimioter. 2020 Apr;33(2):110-115. doi: 10.37201/req/094.2019. Epub 2020 Feb 14. PMID: 32056418; PMCID: PMC7111230.